Stevanato Group S.p.A. (STVN)
Stevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling Upside
Stevanato Group is reiterated as a Buy, driven by robust Q1 results and a compelling long-term growth trajectory. The High-Value Solutions segment accelerated, now comprising 47% of sales, fueled by broad biologics and injectable therapies demand. Management attributed the slowdown in the Engineering segment to project timing and order delays rather than competitive pressure or deteriorating demand. Importantly, segment profitability improved despite lower volumes.
Stevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Stevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Stevanato Group S.p.A. (STVN) Q1 2026 Earnings Call Transcript
Stevanato Group S.p.A. (STVN) Q1 2026 Earnings Call Transcript
Stevanato Group (STVN) Q1 Earnings and Revenues Beat Estimates
Stevanato Group (STVN) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.11 per share a year ago.
Stevanato Group (STVN) Reports Next Week: Wall Street Expects Earnings Growth
Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stevanato Group S.p.A. (NYSE:STVN) Given Consensus Recommendation of “Moderate Buy” by Analysts
Shares of Stevanato Group S.p.A. (NYSE: STVN - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have issued a buy recommendation and
Stevanato: Strong Q4 Results Reinforce Long-Term Growth Story
Stevanato Group is reiterated as a Buy, supported by strong Q4/FY25 results and robust long-term demand drivers. While the Engineering division continues to weigh on margins and reported less than €40m in Q4 sales, the pressure appears cyclical. With ~90% of capex directed toward HVS expansion, the segment has limited impact on the group's long-term fundamentals.
Stevanato Group S.p.A. (STVN) Q4 2025 Earnings Call Transcript
Stevanato Group S.p.A. (STVN) Q4 2025 Earnings Call Transcript
Stevanato Group (STVN) Surpasses Q4 Earnings and Revenue Estimates
Stevanato Group (STVN) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to earnings of $0.2 per share a year ago.
STVN or MDGL: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Drugs sector might want to consider either Stevanato Group (STVN) or Madrigal (MDGL). But which of these two stocks offers value investors a better bang for their buck right now?
Stevanato: Structural Growth Intact, Buy Confirmed
Stevanato's biologics remain the core growth engine supported by a broad pipeline, resilient GLP-1 demand, vial recovery, and a favorable industry backdrop. While Engineering continues to weigh on margins in the short run, the weakness appears cyclical rather than structural, with optimization progressing and limited impact on group fundamentals. After a ~14% pullback, long-term earnings visibility remains strong, supporting higher 2026 profitability assumptions and a higher target price, leading us to maintain a constructive stance.
Stevanato Group S.p.A. (STVN) Q3 2025 Earnings Call Transcript
Stevanato Group S.p.A. ( STVN ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Lisa Miles - Chief Communications & Investor Relations Officer Franco Stevanato - CEO & Executive Chairman Marco Dal Lago - Chief Financial Officer Conference Call Participants Lawrence Solow - CJS Securities, Inc. Matthew Larew - William Blair & Company L.L.C.
